Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

Abstract: This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

Abstract: This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.

Abstract: This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF66 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF66 receptor and having a sequence identical to the sequence of the human SNORF66 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-hSNORF66-f (Patent Deposit Designation No. PTA ______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF66 receptor, wherein the human SNORF66 receptor comprises an amino acid sequence identical to the sequence of the human SNORF66 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (SEQ ID NO: 1).

Abstract: This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF66 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to a nucleic acid encoding a human SNORF66 receptor and having a sequence identical to the sequence of the human SNORF66 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-hSNORF66-f (Patent Deposit Designation No. PTA______). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF66 receptor, wherein the human SNORF66 receptor comprises an amino acid sequence identical to the sequence of the human SNORF66 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (SEQ ID NO: 1).

Abstract: This invention provides isolated nucleic acid molecules encoding Y2 receptors, an isolated, purified Y2 receptor protein, vectors comprising isolated nucleic acid molecules encoding Y2 receptors, mammalian, insect, bacterial and yeast cells comprising such vectors, antibodies directed to the Y2 receptors, nucleic acid probes useful for detecting nucleic acid encoding Y2 receptors, antisense oligonucleotides complementary to unique sequences of a nucleic acid molecule which encodes a Y2 receptor, pharmaceutical compounds related to the Y2 receptors, and nonhuman transgenic animals which express nucleic acid encoding a normal or mutant Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and methods of treatment involving Y2 receptors.

Abstract: The present invention provides a process for identifying a chemical compound which specifically binds to a rat or human 5-HT4 receptor. The invention also provides a process involving competitive binding for identifying a chemical compound which specifically binds to a rat or human 5-HT4 receptor. The invention provides for a process for determining whether a chemical compound specifically binds to and activates a rat or human 5-HT4 receptor. The invention additionally provides for a process for determining whether a chemical compound specifically binds to and inhibits activation of a rat or human 5-HT4 receptor.

Abstract: This invention provides isolated nucleic acid molecules encoding a human and a rat Y2 receptor, an isolated protein which is a human or rat Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human or rat Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human or rat Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human or rat Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human or rat Y2 receptor, pharmaceutical compounds related to human or rat Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human or rat Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human or rat Y2 receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, an isolated protein which is a mammalian 5-HT.sub.4 receptor, an isolated protein which is a human 5-HT.sub.4 receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4 receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4 receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4 receptor, pharmaceutical compounds related to the human 5-HT.sub.4 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4 receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a human Y2 receptor, an isolated protein which is a human Y2 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y2 receptors, mammalian cells comprising such vectors, antibodies directed to the human Y2 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y2 receptors, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y2 receptor, pharmaceutical compounds related to human Y2 receptors, and nonhuman transgenic animals which express DNA a normal or a mutant human Y2 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y2 receptor.

Abstract: This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4A receptor and an isolated nucleic acid molecule encoding a human 5-HT.sub.4A receptor, an isolated protein which is a mammalian 5-HT.sub.4A receptor, an isolated protein which is a human 5-HT.sub.4A receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT.sub.4A receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT.sub.4A receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT.sub.4A receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT.sub.4A receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT.sub.4A receptor, pharmaceutical compounds related to the human 5-HT.sub.4A receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT.sub.4A receptor.